Generation of CML derived iPSCs. (A) Morphology of CML-iPSCs. (B) Immunofluirescence staining shows expression of pluripotent marker (left: SSEA-4 and right: Tra-1-60) in CML-iPSCs. (C) RT-PCR analysis of ES cell marker genes. Endogenous expression of these stem cell–specific genes in CML-iPSCs was verified. (D) CML-iPSCs expressed the BCR-ABL fusion transcript. (E) Imatinib (10μM) were added to the culture of iPSCs. DMSO (top left panel) and imatinib (top right panel) treated CML-iPSCs were shown. The number of alive CML-iPSCs (CML-iPS_1 and CML-iPS_2) and normal iPSCs (Nor-iPS) after 5 days treatment was calculated (bottom panel). These were the representative data from 3 independent experiments.